Lung Cancer Trials Ask AI to find trials
CompletedNot applicableNCT01012401
Official study title

Evaluating an Interactive Cancer Communication System (ICCS) in Lung Cancer

Study summary

This study will examine the potential for an Interactive Cancer Communication System (ICCS) to impact not only psychosocial outcomes such as quality of life but also length of survival in an advanced stage lung cancer population. Two hypotheses will be tested: the Comprehensive Health Enhancement Support System- Lung Cancer (CHESS- LC) will significantly improve patient quality of life and length of overall survival as compared to a usual care control group.

Ask AI to explain this study
Start here

Key things to know

Main goalSupportive Care

This describes the study’s primary purpose.

What is being studiedCHESS website for lung cancer patient + internet access if needed

The study team can explain what participation involves.

Who it may be forLung Cancer, Stage IIIb or IV

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Nov 15, 2019 · Source: ClinicalTrials.gov

Is enrollment open?Completed

Ask the study team to confirm whether enrollment is open.

What kind of study?Not applicable

Interventional

Where is it offered?4 U.S. locations

Locations may change over time.

Who runs it?University of Wisconsin, Madison

Study sponsor

01
Study overview

What this study is about

Purpose
Supportive Care
Study type
Interventional
Phase
Not applicable
Sponsor
University of Wisconsin, Madison
Interventions being studied
Other: CHESS website for lung cancer patient + internet access if needed
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Study topics
Survivorship and quality of life→
03
Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria
  • All patients must be diagnosed with non-small cell lung cancer (Stage IIIA non surgical, IIIB or IV)
  • All patients must be within 12 months of their primary lung cancer diagnosis or metastatic or recurrence disease.
  • All patients must be at least 18 years of age,
  • All patients must have an ECOG Performance Status rating of level 0, 1 or 2.
  • If patients have brain metastases, they must be stable
  • All patients must be under the care of a clinician who has consented to participate in the study.
  • All patients must be able to speak and read English (educational attainment of at least 6th grade).
  • All patients will be invited to have a caregiver also participate in the study, however this is not required.

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • Harry Gray Cancer Center at Hartford HospitalHartford, Connecticut
  • University of Illinois at Chicago Cancer CenterChicago, Illinois
  • M.D. Anderson Cancer CenterHouston, Texas
  • University of Wisconsin Carbone Cancer CenterMadison, Wisconsin

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Nov 15, 2019. Always confirm current availability with the study team.

View original record ↗